stockrowSyndax Pharmaceuticals, Inc.
SNDX Healthcare Biotechnology
Syndax Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $172.4 million, up 627.8% from fiscal 2024.
- Revenue
- +81.6%
- EPS
- +21.4%
- Free cash flow
- +61.4%
- Total debt
- +71.1%
Quarter to September 2026, against a year earlier
Follow SNDX
Alert me
Syndax Pharmaceuticals, Inc. (SNDX) EV/Sales
As of 6 November 2026, Syndax Pharmaceuticals, Inc. (SNDX) trades at a EV/Sales of 3.6×. Over the past ten years it has ranged from −84.0× (June 2016) to 689× (April 2021); the current reading is higher than 6% of that period. That is below the Biotechnology industry median of 9.0× and in line with the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 10.3× | 73.17% |
| FY2024 | 5.9× | 16.41% |
| FY2021 | 5.1× | (98.80%) |
| FY2020 | 426× | 209.17% |
| FY2019 | 138× | 356.33% |
| FY2018 | 30.2× | (6.39%) |
| FY2017 | 32.2× | 155.18% |
| FY2016 | 12.6× | — |
| FY2015 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 6.4× | (19.03%) |
| Jun 2026 | 7.9× | (16.54%) |
| Mar 2026 | 9.5× | (7.47%) |
| Dec 2025 | 10.3× | (6.15%) |
| 33 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LTGO Latigo Biotherapeutics Inc compare | n/m |
| CRVS Corvus Pharmaceuticals, Inc. compare | n/m |
| ANRO Alto Neuroscience, Inc. compare | n/m |
| IVA Inventiva S.A. Sponsored ADR compare | 1.5× |
| MGTX MeiraGTx Holdings PLC compare | 2.0× |
| PHAR Pharming Group N.V. Sponsored ADR compare | 2.0× |
| RIGL Rigel Pharmaceuticals, Inc. compare | 2.3× |
| SNDX Syndax Pharmaceuticals, Inc. | 3.6× |
| AKTS Aktis Oncology, Inc. compare | 36.8× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)